Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis	Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, histiocytosis, interstitial lung disease, lung disorder, lymphatic system disorder, respiratory system disorder	Active, not recruiting	Phase 2	2026-10-07		NCT04943198

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Anna Raciborska	5
Maria Sklodowska-Curie National Research Institute of Oncology	28
Wroclaw University of Environmental and Life Sciences	3
Łukasiewicz Research Network	3

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Mother and Child Institute	Warsaw	Poland	4